Not for Retail distribution: this document is intended exclusively for Professional, Institutional, Qualified or Wholesale Investors / Clients, as defined by applicable local laws and regulation. Circulation must be restricted accordingly

## AI & Metaverse strategy Sovereign AI projects are accelerating globally as countries recognise AI infrastructure as a strategic priority

- Global equity markets continued to rise in June with outperformance of our AI strategy
- The 'Enablers' sub-theme was strong over the month, in particular AI related semiconductors
- We continued to refine the portfolio toward companies with more direct AI exposure

Pauline Llandric, James Dowey co-Portfolio Manager, AI & Metaverse Strategy

## What's happening?

Global equity markets continued to rise in June, with the MSCI All Country World Total Return Index gaining 4.5%<sup>1</sup> in USD terms, capping a positive but volatile first half of 2025 (10.3% return for the MSCI All Country World Total Return Index in USD terms). Market sentiment improved as the Trump administration adopted a more conciliatory stance on trade policy, signalling potential progress in negotiations with China and hinting at near-term deals. While geopolitical tensions in the Middle East remained elevated, markets responded positively to strengthening leading indicators of both consumer and business confidence.

## Portfolio positioning and performance

The AI & Metaverse strategy outperformed the MSCI All Country World Index during the month. Both subthemes 'Applications' and 'Enablers' contributed to performance, with Enablers being the strongest contributor. Several AI related semiconductors (such as Nvidia, Broadcom and TSMC) reached new all-time highs as investor confidence in the AI infrastructure buildout strengthened.

Within key contributors, Nvidia, the leading AI chip designer, performed strongly and management meeting as well as GTC Paris (Nvidia's technology event) reinforced our investment thesis on multiple fronts. First, the company has successfully resolved supply chain challenges that had constrained availability of current generation products. Second, the new Blackwell product ramp is exceeding expectations, with sovereign AI projects accelerating globally as countries recognise AI infrastructure as a strategic priority. Management now has visibility to approximately \$1.5<sup>2</sup> trillion of AI infrastructure investment in coming years. Third, and perhaps most importantly, we are witnessing a dramatic shift toward inference

<sup>&</sup>lt;sup>1</sup> Source: Bloomberg as of 30/06/2025 in USD

<sup>&</sup>lt;sup>2</sup> Source: NVIDIA GTC Paris, 11/06/2025



workloads as enterprises move from model training to deployment. CEO Jensen Huang revealed that inference token generation has exploded 50-100x<sup>3</sup> in the past year, with Microsoft alone processing over 100 trillion tokens last quarter (which is five times more than a year ago). This transition to inference, combined with upcoming product refresh cycle, should sustain robust demand momentum.

Japanese semiconductor testing equipment manufacturer Advantest also performed strongly over the period as the company benefits from the increasing complexity of AI chips that require more sophisticated testing solutions. The shift towards advanced packaging and chiplet designs is driving demand for their testing platforms.

Roblox, the user-generated gaming platform, delivered solid performance as its AI-powered creation tools continue to attract both developers and players. The game experience "Grow a Garden" broke industry records with over 20 million concurrent players, surpassing previous peaks seen in Fortnite and other major titles. This further demonstrates the platform's ability to generate viral, engaging content that drives monetisation.

Within key detractors, AppLovin, the mobile app monetisation and marketing platform was weak following its exclusion from the S&P 500 index despite market expectations for inclusion. The company's fundamentals remain strong with its Aldriven advertising optimisation tools continuing to gain market share.

Trip.com, the Chinese online travel agent was weak as fears rose over increased competition coming from JD.com within China. Whilst we believe Trip has established a strong long term competitive moat in the domestic and international Chinese travel markets, this could result in a period of near term pressure on the business. Our experience suggests that this competitive step up is often short lived but we will continue to monitor how this develops.

During the month, we continued to refine the portfolio toward companies with more direct AI exposure.

In healthcare, we exited positions in medical technology companies Penumbra and Enovis to purchase Recursion Pharmaceuticals, which uses AI and machine learning to accelerate drug discovery, and Procept BioRobotics, which combines AI-guided imaging with robotic surgery for prostate procedures.

Within financials, we sold payment network company Mastercard and invested the proceeds into Upstart, a lending platform that uses AI to assess credit risk beyond traditional credit scores.

In cybersecurity, we exited Palo Alto Networks and Crowdstrike and purchased CyberArk, which specialises in identity security and privileged access management. As AI systems proliferate, securing machine identities and automated workflows becomes critical.

Within semiconductor capital equipment, we sold positions in Lam Research, Applied Materials and ASML and purchased ASM International, as well as increased our exposure to Advantest. ASM's atomic layer deposition technology is essential for manufacturing the advanced chips used in AI applications.

## Outlook

The AI and Metaverse landscape continues to evolve rapidly, with recent developments highlighting the breakneck pace of innovation, intense competition and global strategic significance of AI. Structurally, we believe the stock market gains from AI will broaden out over time from the companies involved in the infrastructure build-out as the deployment of downstream

-

<sup>&</sup>lt;sup>3</sup> Source : NVIDIA GTC Paris, 11/06/2025



Al applications picks up. We view Al as a general purpose technology with applications and value creation that will be realised across most of the economy.

President Trump's tariffs present both challenges and opportunities for the AI sector. While semiconductors remain largely exempt, increased costs for data center hardware and networking equipment may require companies to adapt their strategies. Though these tariffs may temporarily impact growth as companies absorb costs or reconsider supply chains, the persistent strong demand for AI capabilities will likely drive innovation in sourcing and potentially accelerate domestic production capabilities. Over time, we believe this could strengthen the resilience of the AI supply chain and create new investment opportunities in onshore manufacturing.

The strategy maintains a balanced exposure to both enabling technologies and innovative applications, with a continued focus on companies demonstrating clear competitive advantages and tangible AI-driven growth opportunities. We believe this positioning allows us to capture both the infrastructure build out and the longer-term application deployment phases of the AI revolution, while navigating the evolving trade and regulatory landscape.

Stock/company examples are for explanatory/illustrative purposes only. They should not be viewed as investment advice or a recommendation from AXA IM. These examples do not represent all of the securities purchased, sold or recommended for the client's accounts. No representation is made that these were or will be profitable.

No assurance can be given that the AI & Metaverse strategy will be successful. Investors can lose some or all of their capital invested. The Metaverse is subject to risks including Equity; Emerging Markets; Global Investments; Investments in small and/or micro capitalisation universe; Investments in specific sectors or asset classes; ESG; Investment through the Stock Connect program.

Not for Retail distribution: This document is intended exclusively for Professional, Institutional, Qualified or Wholesale Clients / Investors only, as defined by applicable local laws and regulation. Circulation must be restricted accordingly.

Past performance is not a guide to current or future performance, and any performance or return data displayed does not take into account commissions and costs incurred when issuing or redeeming units. The value of investments, and the income from them, can fall as well as rise and investors may not get back the amount originally invested. Exchange-rate fluctuations may also affect the value of their investment. Due to this and the initial charge that is usually made, an investment is not usually suitable as a short term holding.

This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities. The strategies discussed in this document may not be available in your jurisdiction.

Due to its simplification, this document is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee forecasts made will come to pass. Data, figures, declarations, analysis, predictions and other information in this document is provided based on our state of knowledge at the time of creation of this document. Whilst every care is taken, no representation or warranty (including liability towards third parties), express or implied, is made as to the accuracy, reliability or completeness of the information contained herein. Reliance upon information in this material is at the sole discretion of the recipient. This material does not contain sufficient information to support an investment decision.

Please note that the management company reserves the right, at any time, to no longer market the product(s) mentioned in this communication in a European Union country by notification to its authority of supervision in accordance with European passport rules. In the event of dissatisfaction with the products or services, you have the right to make a complaint either with the marketer or directly with the management company (more information on our complaints policy available in English here). You also have the right to take legal or extra-judicial action at any time if you reside in one of the countries of the European Union. The



For professional clients only
June 2025
Monthly Perspectives
AXA IM Equity

European online dispute resolution platform allows you to enter a complaint form (by clicking <u>here</u>) and informs you, depending on your jurisdiction, about your means of redress (by clicking <u>here</u>).

Issued in the U.K. by AXA Investment Managers UK Limited, which is authorised and regulated by the Financial Conduct Authority in the UK. Registered in England and Wales, No: 01431068. Registered Office: 22 Bishopsgate, London, EC2N 4BQ. In other jurisdictions, this document is issued by AXA Investment Managers SA's affiliates in those countries.

In Hong Kong, this document is issued by AXA Investment Managers Asia Limited (SFC License No. AAP809), which is authorized and regulated by Securities and Futures Commission. This document is to be used only by persons defined as "professional investor" under Part 1 of Schedule 1 to the Securities and Futures Ordinance (SFO) and other regulations, rules, guidelines or circulars which reference "professional investor" as defined under Part 1 of Schedule 1 to the SFO. This document must not be relied upon by retail investors. Circulation must be restricted accordingly.

In Singapore, this document is issued by AXA Investment Managers Asia (Singapore) Ltd. (Registration No. 199001714W) and is intended for the use of Institutional Investors only as defined in Section 4A of the Securities and Futures Act (Cap. 289) and must not be relied upon by retail investors. Circulation must be restricted accordingly.

This document has been issued by AXA Investment Managers Asia (Singapore) Ltd (ARBN 115203622) ("AXA IM Asia"). AXA IM Asia is exempt from the requirement to hold an Australian Financial Services License and is regulated by the Monetary Authority of Singapore under Singaporean laws, which differ from Australian laws. AXA IM Asia offers financial services in Australia only to residents who are "wholesale clients" within the meaning of Corporations Act 2001 (Cth).

For Japanese clients: AXA Investment Managers Japan Ltd., whose registered office and principal place of business is at NBF Platinum Tower 14F 1-17-3 Shirokane, Minato-ku, Tokyo 108-0072, Japan, which is registered with the Financial Services Agency of Japan under the number KANTOZAIMUKYOKUCHO (KINSHO) 16, and is a member of Japan Securities Dealers Association, Type II Financial Instrument Firms Association, Investment Trust Association of Japan and Japan Investment Advisors Association to carry out the regulated activity of Financial Instrument Business under the Financial Instrument Exchange Law of Japan. In Japan, none of the funds mentioned in this document are registered under the Financial Instrument Exchange Law of Japan or Act on Investment Trusts and Investment Corporations. This document is purely for the information purpose for use by Qualified Institutional Investors defined by the Financial Instrument Exchange Law of Japan.

In Korea, AXA Investment Managers Asia (Singapore) Ltd is a registered Cross Border Investment Advisor/Discretionary Investment Management Company under the Financial Investment Services and Capital Markets Act (the "Act"). The activities referenced under the Act are 5-2-2 Investment Advisory Business and 6-2-2 Discretionary Investment Management Business, respectively. Its financial services are available in Korea only to Professional Investors within the meaning of Article 10 of Enforcement Decree of the Financial Investment Services and Capital Markets Act.

To the extent that any fund is mentioned in this document, neither the fund nor AXA IM Asia is making any representation with respect to the eligibility of any recipients of this document to acquire the units/shares in the fund under the laws of Korea, including but without limitation the Foreign Exchange Transaction Act and Regulations thereunder. The units/shares have not been registered under the Financial Investment Services and Capital Markets Act of Korea, and none of the units/shares may be offered, sold or delivered, or offered or sold to any person for re-offering or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to applicable laws and regulations of Korea.

In Taiwan, this document is issued by AXA Investment Managers Asia Limited (SFC License No. AAP809), which is authorized and regulated by Securities and Futures Commission. This document and the information contained herein are intended for the use of professional or institutional investors and should not be relied upon by retail investors. They have been prepared and issued for private informational and educational purposes only at the sole request of the specified recipients, and not intended for general circulation. They are strictly confidential, and must not be reproduced, circulated, distributed, redistributed or otherwise used, in whole or in part, in any way without the prior written consent of AXA IM Asia. They are not intended for distribution to any persons or in any jurisdictions for which it is prohibited.

If any fund is highlighted in this communication (the "Fund"), its offering document or prospectus contains important information on selling restrictions and risk factors, you should read them carefully before entering into any transaction. It is your responsibility to be aware of and to observe all applicable laws and regulations of any relevant jurisdiction. AXA IM Asia does not intend to offer any Fund in any country where such offering is prohibited.

The offer, distribution, sale or re-sale of fund units/shares in Taiwan requires approval from and/or registration with Taiwanese regulatory authorities. To the extent that any units/shares of the Funds are not so licensed or registered, such units/shares are made available in Taiwan on a private placement basis only to banks, bills houses, trust enterprises, financial holding companies and other qualified entities or institutions (collectively, "Qualified Institutions") and other entities and individuals meeting specific criteria ("Other Qualified Investors") pursuant to the private placement provisions of the Rules Governing Offshore Funds. No other offer or sale of such units/shares in Taiwan is permitted. Taiwanese purchasers of such units/shares may not sell or otherwise dispose of their holdings except by redemption, transfer to a Qualified Institution or Other Qualified Investor, transfer by operation of law or other means approved by the Taiwan Financial Supervisory Commission.

For Malaysian investors: as the recognition by the Malaysian Securities Commission pursuant to Section 212 of the Malaysian Capital Markets and Services Act 2007 has not been / will not be obtained nor will this document be lodged or registered with the Malaysian Securities Commission, the shares referred to hereunder (if any) are not being and will not be deemed to be issued, made available, offered for subscription or purchase in Malaysia and neither this document nor any other document or other material in connection therewith should be distributed, caused to be distributed or circulated in Malaysia.

For Thailand investors: nothing in this document shall constitute in any manner whatsoever a proposal to make available, offer for subscription or purchase or to issue an invitation to purchase or subscribe for any securities in Thailand or a proposal to implement any of the foregoing in Thailand nor has this document been approved by or registered with the Securities and Exchange Commission of Thailand ("SEC"). No person receiving a copy of this document may treat the same as constituting an invitation or offer to him in Thailand and such person shall not distribute or make available this document in Thailand. The issuer of this document shall not be liable in any manner whatsoever in the event this document is distributed or made available to any person in Thailand receiving a copy of this document. Since no application for approval has been or will be made to the SEC for the offering of the securities, or for the registration of this document, the securities shall

For professional clients only
June 2025
Monthly Perspectives
AXA IM Equity

not be offered for subscription or purchased or made available, whether directly or indirectly, in Thailand. It is the sole responsibility of recipients wishing to take any action upon this document to satisfy themselves as to the full observance of the laws of Thailand, to comply with all relevant government and regulatory approvals, and to comply with all applicable laws, including but not limited to exchange control laws.

For Investors in People's Republic of China (PRC): this document does not constitute a public offer of the product, whether by sale or subscription in the PRC. The product is not being offered or sold directly or indirectly in the PRC to or for the benefit of, legal or natural persons of the PRC. Further, no legal or natural persons of the PRC may directly or indirectly purchase any of the product or any beneficial interest herein without obtaining all prior PRC's governmental approvals that are required, whether statutorily or otherwise. Persons who come into possession of this document are required by the issuer and its representatives to observe these restrictions.

For Brunei investors: This document has not been delivered to, licensed or permitted by Autoriti Monetari Brunei Darussalam. Nor has it been registered with the Registrar of Companies. This document is for informational purposes only and does not constitute an invitation or offer to the public. As such, it must not be distributed or redistributed to and may not be relied upon or used by any person in Brunei other than the person to whom it is directly communicated and who belongs to a class of persons as defined under Section 20 of the Brunei Securities Market Order, 2013.

For Filipino investors: The shares or units referred to in this document (if any) have not been registered with the Securities and Exchange Commission under the Securities Regulation Code. Any future offer or sale thereof is subject to registration requirements under the Code unless such offer or sale qualifies as an exempt transaction.

For Vietnam investors: This document does not contemplate an offer to sell the interests in any funds in Vietnam. The document has not been approved by the State Securities Commission of Vietnam or any other competent authorities in Vietnam which takes no responsibility for its contents. No offer to purchase the interests in any funds will be made in Vietnam and this document is intended to be read by the addressee only and must not be passed to, issued to, or shown to the public generally. The value of the interests in any funds, the possibility of gaining profit and the level of risk stipulated in this document is purely for reference purposes only and may change at any time depending on market status. Investment in fund(s) does not carry any assurance that investors will make a profit. Investors should themselves carefully balance the risks and the level of those risks before they make any decision to invest in any funds. It is investors' responsibilities to ensure that they are eligible to make investment in any funds. Investors are responsible for obtaining all applicable approvals and complying with requirements under Vietnamese laws.

MSCI: Neither MSCI nor any other party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in or related to compiling, computing or creating the data have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the MSCI data is permitted without MSCI's express written consent.